Delivery Order HHSN261201700011I-HHSN26100002

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $149,535.00 Firm Fixed Price Delivery Order contract to Societal CDMO San Diego, LLC, a self-certified small disadvantaged business, for the GMP production of 40 mg z-endoxifen (NSC 774768) capsules. This Delivery Order contract is associated with the larger Drug Formulation and Manufacturing Contracts 2019 indefinite delivery contract vehicle. The contract supports the development and...

This is a $36,506,288.06 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to Theradex Systems, Inc. for clinical trials monitoring services. The contract has a performance period from May 1, 2017 to April 30, 2022. The contract supports NCI's Experimental Therapeutics Clinical Trials Network (ETCTN), National Clinical Trials Network (NCTN), and National Community Oncology Research Program (NCORP), as well as the NCI COVID-19 in Cancer Patients Study (NCCAPS) and the...

This firm fixed-price purchase order was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Cyprotex US LLC, a foreign-owned for-profit contract research organization. The $157,158 contract is for the characterization of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of small-molecule drug candidates using standardized in vitro methods. This work supports...

Xenobiotic Laboratories Inc. was awarded a firm fixed price delivery order against the Analytical Services Center for Medications Development Program for analytical services. The delivery order, valued at $0.00 with a period of performance from September 25, 2019 through May 23, 2022, was issued by the National Institute on Drug Abuse, part of the Department of Health and Human Services National Institutes of Health. Under the delivery order, Xenobiotic Laboratories Inc.'s Biotesting Division...

This is a firm-fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, to Cyprotex US LLC, a foreign-owned for-profit contract research organization. The $109,392.00 contract is for compound testing services, including plasma protein binding studies, PXR and AhR activation studies, and CYP inhibition assays on various small molecule compounds. This work supports NIDA's mission to seek fundamental...

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $1.7 million delivery order contract to Regimed Medical to procure 240 blister packs of 150 mg nilotinib tablets and 40 blister packs of 200 mg nilotinib tablets in support of the Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program. The firm fixed price contract runs from November 17, 2023 through November 16, 2024 and will be performed in Frederick, Maryland.

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $12,075.00 firm fixed price purchase order contract to Eurofins Pharma Bioanalytics Services US, LLC, a foreign-owned for-profit organization, for laboratory analysis services. The contract has a period of performance ending on March 19, 2026 and was awarded on March 20, 2025. This contract does not have a set-aside designation.</p>

This is a federal contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services (HHS), to Cyprotex US LLC, a leading contract research organization specializing in predictive toxicology and ADME (absorption, distribution, metabolism, and excretion) research. The $18,024.00 firm fixed-price purchase order contract is for the testing of two compounds against key ADME and DMPK (drug metabolism and...

This is a $9,572,707.00 definitive, cost-plus-fixed-fee contract awarded by the National Institute on Drug Abuse (NIDA) to Research Triangle Institute (RTI International) for analytical chemistry and stability testing services related to substance use disorder treatment drugs. The contract has an ultimate completion date of August 3, 2029. The contract supports the development and validation of analytical methods, reference standard preparation, physical and chemical characterization, quality...

This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...